Format
Sort by
Items per page

Send to

Choose Destination

Best matches for maastro:

Radiomics: the bridge between medical imaging and personalized medicine. Lambin P et al. Nat Rev Clin Oncol. (2017)

LC3/GABARAP family proteins: autophagy-(un)related functions. Schaaf MB et al. FASEB J. (2016)

Combining radiotherapy with immunotherapy: the past, the present and the future. Van Limbergen EJ et al. Br J Radiol. (2017)

Search results

Items: 1 to 20 of 769

1.

Moving Breast Cancer Therapy up a Notch.

Mollen EWJ, Ient J, Tjan-Heijnen VCG, Boersma LJ, Miele L, Smidt ML, Vooijs MAGG.

Front Oncol. 2018 Nov 20;8:518. doi: 10.3389/fonc.2018.00518. eCollection 2018. Review.

2.

Murine vs human tissue compositions: implications of using human tissue compositions for photon energy absorption in mice.

Schyns LE, Eekers DB, van der Heyden B, Almeida IP, Vaniqui A, Verhaegen F.

Br J Radiol. 2018 Nov 30:20180454. doi: 10.1259/bjr.20180454. [Epub ahead of print]

PMID:
30500286
3.

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial.

Eekers DBP, Roelofs E, Cubillos-Mesías M, Niël C, Smeenk RJ, Hoeben A, Minken AWH, Granzier M, Janssens GO, Kaanders JHAM, Lambin P, Troost EGC.

Acta Oncol. 2018 Nov 26:1-9. doi: 10.1080/0284186X.2018.1529424. [Epub ahead of print]

PMID:
30474448
4.

Prognostic Models for Patient Selection in Postoperative Radiotherapy: Ready for Use?

Billiet C, Dirix P, Meijnders P, De Ruysscher D.

J Thorac Oncol. 2018 Dec;13(12):1809-1811. doi: 10.1016/j.jtho.2018.09.018. No abstract available.

PMID:
30467043
5.

Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells.

Sosa Iglesias V, Theys J, Groot AJ, Barbeau LMO, Lemmens A, Yaromina A, Losen M, Houben R, Dubois L, Vooijs M.

Front Oncol. 2018 Nov 7;8:460. doi: 10.3389/fonc.2018.00460. eCollection 2018.

6.

Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy.

Vanneste BGL, Buettner F, Pinkawa M, Lambin P, Hoffmann AL.

Clin Transl Radiat Oncol. 2018 Nov 3;14:17-24. doi: 10.1016/j.ctro.2018.10.006. eCollection 2019 Jan.

7.

External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer.

Foley KG, Shi Z, Whybra P, Kalendralis P, Larue R, Berbee M, Sosef MN, Parkinson C, Staffurth J, Crosby TDL, Roberts SA, Dekker A, Wee L, Spezi E.

Radiother Oncol. 2018 Nov 10. pii: S0167-8140(18)33557-6. doi: 10.1016/j.radonc.2018.10.033. [Epub ahead of print]

PMID:
30424894
8.

Pathway-based subnetworks enable cross-disease biomarker discovery.

Haider S, Yao CQ, Sabine VS, Grzadkowski M, Stimper V, Starmans MHW, Wang J, Nguyen F, Moon NC, Lin X, Drake C, Crozier CA, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW, Kasprzyk A, Lambin P, Lio' P, Bartlett JMS, Boutros PC.

Nat Commun. 2018 Nov 12;9(1):4746. doi: 10.1038/s41467-018-07021-3.

9.

Vulnerabilities of radiomic signature development: The need for safeguards.

Welch ML, McIntosh C, Haibe-Kains B, Milosevic MF, Wee L, Dekker A, Huang SH, Purdie TG, O'Sullivan B, Aerts HJWL, Jaffray DA.

Radiother Oncol. 2018 Nov 8. pii: S0167-8140(18)33551-5. doi: 10.1016/j.radonc.2018.10.027. [Epub ahead of print]

10.

A systematic review comparing radiation toxicity after various endorectal techniques.

Verrijssen AS, Opbroek T, Bellezzo M, Fonseca GP, Verhaegen F, Gerard JP, Sun Myint A, Van Limbergen EJ, Berbee M.

Brachytherapy. 2018 Nov 2. pii: S1538-4721(18)30526-9. doi: 10.1016/j.brachy.2018.10.001. [Epub ahead of print] Review.

PMID:
30396854
11.

The effect of different image reconstruction techniques on pre-clinical quantitative imaging and dual-energy CT.

Vaniqui A, Schyns LEJR, Almeida IP, van der Heyden B, Podesta M, Verhaegen F.

Br J Radiol. 2018 Nov 7:20180447. doi: 10.1259/bjr.20180447. [Epub ahead of print]

PMID:
30394804
12.

The impact of training and professional collaboration on the interobserver variation of lung cancer delineations: a multi-institutional study.

Mercieca S, Belderbos JSA, van Baardwijk A, Delorme S, van Herk M.

Acta Oncol. 2018 Oct 30:1-9. doi: 10.1080/0284186X.2018.1529422. [Epub ahead of print]

PMID:
30375905
13.

Exploring the feasibility of a clinical proton beam with an adaptive aperture for pre-clinical research.

Almeida IP, Vaniqui A, Schyns LE, van der Heyden B, Cooley J, Zwart T, Langenegger A, Verhaegen F.

Br J Radiol. 2018 Nov 7:20180446. doi: 10.1259/bjr.20180446. [Epub ahead of print]

PMID:
30362812
14.

ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NC, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher D, Sculier JP, Schepereel A, Subotic D, Van Schil P, Blum TG.

Eur Respir J. 2018 Oct 25. pii: 1800610. doi: 10.1183/13993003.00610-2018. [Epub ahead of print]

PMID:
30361252
15.

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.

Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V, Ruben J, Lau E, Hofman MS, De Abreu Lourenco R, Sridharan S, Brook NR, Martin J, Lawrentschuk N, Kron T, Foroudi F.

BMC Cancer. 2018 Oct 23;18(1):1030. doi: 10.1186/s12885-018-4916-2.

16.

Clinical implementations of 4D pencil beam scanned particle therapy: Report on the 4D treatment planning workshop 2016 and 2017.

Trnková P, Knäusl B, Actis O, Bert C, Biegun AK, Boehlen TT, Furtado H, McClelland J, Mori S, Rinaldi I, Rucinski A, Knopf AC.

Phys Med. 2018 Oct;54:121-130. doi: 10.1016/j.ejmp.2018.10.002. Epub 2018 Oct 8.

17.

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).

van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J.

Radiother Oncol. 2018 Oct 13. pii: S0167-8140(18)33502-3. doi: 10.1016/j.radonc.2018.09.019. [Epub ahead of print]

PMID:
30327236
18.

Towards a modular decision support system for radiomics: A case study on rectal cancer.

Gatta R, Vallati M, Dinapoli N, Masciocchi C, Lenkowicz J, Cusumano D, Casá C, Farchione A, Damiani A, van Soest J, Dekker A, Valentini V.

Artif Intell Med. 2018 Oct 3. pii: S0933-3657(17)30593-6. doi: 10.1016/j.artmed.2018.09.003. [Epub ahead of print]

PMID:
30292538
19.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
20.

Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.

de Jong EEC, van Elmpt W, Rizzo S, Colarieti A, Spitaleri G, Leijenaar RTH, Jochems A, Hendriks LEL, Troost EGC, Reymen B, Dingemans AC, Lambin P.

Lung Cancer. 2018 Oct;124:6-11. doi: 10.1016/j.lungcan.2018.07.023. Epub 2018 Jul 20.

Supplemental Content

Loading ...
Support Center